Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU + Endothelial Cells as Key Players in Tumor Progression
Cancer Science · 2025
DOI: 10.1111/cas.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Zhehao Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Genetic Heterogeneity, Endothelial Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Foundation of Spring Sunshine Program-Cooperative Research Project of the Ministry of Education, Graduate Education and Teaching Reform Project of Central South University, Innovation and entrepreneurship education teaching reform research project of Central South University.
Abstract (Originalsprache)
Osteosarcoma is a common malignant bone tumor in children and adolescents, characterized by high heterogeneity and poor prognosis. The role of intratumoral heterogeneity (ITH) in osteosarcoma progression remains poorly understood. To explore this, we collected paired tumor tissue samples from the central region (CR) and peripheral region (PR) of six osteosarcoma patients and performed single‐cell RNA sequencing. Our findings reveal significant microenvironmental differences between these regions. The CR harbors a higher proportion of tumor cells, while the PR contains a higher proportion of endothelial cells, particularly the CLU+ subcluster. Functionally, the CR hosts a higher proportion of immune‐activated myeloid cells and tumor‐infiltrating lymphocytes (TILs), whereas the tumor cells in the PR show increased activation of hypoxia‐related pathways. In the PR, CLU+ endothelial cells (CLU+_ECs) promote tumor metastasis by interacting with tumor cells through various ligands, including collagen family members, via ITGB1. Furthermore, CLU+_ECs induce CD8+ T cell exhaustion via the Nectin2‐TIGIT pathway, suppressing the anti‐tumor immune response. Overall, our study highlights the substantial spatial heterogeneity in osteosarcoma and identifies CLU+_ECs in the peripheral region as promising therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
- Hunan Key Laboratory of Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Image Processing Center, Beihang University, Beijing, China.
- State Key Laboratory of Virtual Reality Technology and Systems, Beihang University, Beijing, China.
- Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing, China.
- Department of Orthopedics, the Second Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Peng Xie
Förderung
- the Foundation of Spring Sunshine Program-Cooperative Research Project of the Ministry of Education
- Graduate Education and Teaching Reform Project of Central South University
- Innovation and entrepreneurship education teaching reform research project of Central South University
- Hunan Provincial Health Commission Research Project
- Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China
Zitieren
APA
Dai, Z., Xie, P., Bai, X., Liu, T., Guo, X., Kuang, L., Mu, P., & Lu, F. (2025). Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU + Endothelial Cells as Key Players in Tumor Progression. Cancer Science. https://doi.org/10.1111/cas.70138
Vancouver
Dai Z, Xie P, Bai X, Liu T, Guo X, Kuang L, et al. Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU + Endothelial Cells as Key Players in Tumor Progression. Cancer Science. 2025. doi:10.1111/cas.70138
BibTeX
@article{Dai2025,
author = {Dai, Zhehao and Xie, Peng and Bai, Xiangzhi and Liu, Tang and Guo, Xiaoning and Kuang, Lei and Mu, Ping and Lu, Fangjin},
title = {Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU + Endothelial Cells as Key Players in Tumor Progression},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70138}
}
EUVIMED